Get the Stockscreener App
1.82
2.15%
-0.04
After Hours:
1.82
Pyxis Oncology Inc stock is traded at $1.82, with a volume of 723.15K.
It is down -2.15% in the last 24 hours and up +75.00% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.86
Open:
$1.84
24h Volume:
723.15K
Relative Volume:
1.19
Market Cap:
$112.87M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.9891
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
-4.71%
1M Performance:
+75.00%
6M Performance:
+63.96%
1Y Performance:
-50.00%
1-Day Range:
$1.76
$1.92
1-Week Range:
$1.75
$2.00
52-Week Range:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.82 | 115.97M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Does Pyxis Oncology Inc. fit your quant trading modelWeekly Trade Recap & Fast Entry High Yield Tips - Newser
What recovery options are there for Pyxis Oncology Inc.Oil Prices & Capital Protection Trade Alerts - Newser
Detecting price anomalies in Pyxis Oncology Inc. with AIBuy Signal & Accurate Entry and Exit Point Alerts - Newser
Order flow analysis tools used on Pyxis Oncology Inc.July 2025 Sentiment & Entry Point Confirmation Alerts - Newser
Real time social sentiment graph for Pyxis Oncology Inc.2025 Technical Patterns & Fast Entry High Yield Tips - Newser
Published on: 2025-09-12 17:12:16 - Newser
Applying big data sentiment scoring on Pyxis Oncology Inc.Stock Surge & Breakout Confirmation Trade Signals - Newser
Tools to assess Pyxis Oncology Inc.’s risk profile2025 AllTime Highs & Daily Volume Surge Trade Alerts - Newser
Analyzing recovery setups for Pyxis Oncology Inc. investorsQuarterly Earnings Summary & Short-Term High Return Strategies - Newser
Does Pyxis Oncology Inc. show high probability of reboundJuly 2025 PreEarnings & Consistent Profit Trading Strategies - Newser
American Century Companies Inc. Sells 273,584 Shares of Pyxis Oncology, Inc. $PYXS - MarketBeat
Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) (NASDAQ:PYXS) - Seeking Alpha
Is Pyxis Oncology Inc. building a consolidation baseEarnings Miss & Community Driven Trade Alerts - Newser
How to recover losses in Pyxis Oncology Inc. stockJuly 2025 News Drivers & Risk Managed Investment Strategies - Newser
Is Pyxis Oncology Inc. still worth holding after the dipJuly 2025 Volume & Growth Focused Stock Reports - Newser
Is Pyxis Oncology Inc. stock entering bullish territory2025 Support & Resistance & Safe Entry Trade Signal Reports - Newser
Pyxis Oncology (NASDAQ:PYXS) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Best data tools to analyze Pyxis Oncology Inc. stock2025 Buyback Activity & Fast Gain Stock Trading Tips - Newser
What institutional flow reveals about Pyxis Oncology Inc.July 2025 Fed Impact & Verified Momentum Watchlists - Newser
Using RSI to spot recovery in Pyxis Oncology Inc.2025 Price Action Summary & Free Real-Time Volume Trigger Notifications - Newser
Real time scanner hits for Pyxis Oncology Inc. explainedTrade Entry Summary & Precise Buy Zone Identification - Newser
Is now a turning point for Pyxis Oncology Inc.Rate Hike & Daily Stock Trend Reports - Newser
Is it too late to sell Pyxis Oncology Inc.Weekly Profit Analysis & Consistent Growth Equity Picks - Newser
Short interest data insights for Pyxis Oncology Inc.Dip Buying & Free Reliable Trade Execution Plans - Newser
Will Pyxis Oncology Inc. benefit from macro trendsJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - Newser
How to use Fibonacci retracement on Pyxis Oncology Inc.July 2025 Reactions & Consistent Return Strategy Ideas - Newser
Can technical indicators confirm Pyxis Oncology Inc.’s reversalVolume Spike & Long-Term Safe Investment Plans - Newser
Pyxis Oncology Inc. stock prediction for this weekMarket Trend Report & Verified High Yield Trade Plans - Newser
Custom strategy builders for tracking Pyxis Oncology Inc.2025 Investor Takeaways & Short-Term Trading Alerts - Newser
Heatmap analysis for Pyxis Oncology Inc. and competitorsBull Run & Risk Managed Trade Strategies - Newser
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):